COMMUNIQUÉS West-GlobeNewswire

Gain Therapeutics Announces Oral Poster Presentation at IAPRD 2025 30th World Congress on Parkinson’s Disease and Related Disorders
30/04/2025
BETHESDA, Md., April 30, 2025 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of [...]
First AI-Driven Cognitive and Speech Therapy Platform for Spanish, English-Speaking Indian Communities
30/04/2025
Constant Therapy removes language barriers for non-native speakers with stroke, brain injury, or neurological conditions LEXINGTON, Mass., April 30, 2025 (GLOBE NEWSWIRE) -- Constant Therapy Health , a pioneer in [...]
Appendix 4C – Q3 FY25 Quarterly Cash Flow Report
30/04/2025
Highlights Reported positive topline data for ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System Atrophy (MSA) led by robust clinical efficacy Phase 2 data featured in an oral presentation at [...]
BriaCell Reports “Late-Breaker” Phase 3 Data at AACR 2025: Positive Tolerability Profile and Potential Response Biomarkers Identified
30/04/2025
Phase 3 clinical data shows potential predictive biomarkers for treatment response, first identified in Phase 2 study Biomarkers could be utilized to predict and provide better patient outcomes, including response rates [...]
Er-Kim Announces Exclusive Distribution Agreement with Puma Biotechnology to Commercialize NERLYNX® (neratinib) for Breast Cancer Patients
30/04/2025
This collaboration will provide early-stage HER2-positive breast cancer patients with access to the targeted therapy that can reduce the risk of cancer recurrence and spread ATHENS, Greece and LOS ANGELES, April 30, [...]
Mountainside Joins Northwell Direct Network to Offer Best-in-Class Addiction Treatment
30/04/2025
NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- Mountainside Treatment Center is pleased to be named an in-network provider with Northwell Direct, owned by Northwell Health, New York State’s largest healthcare provider and [...]
DEBRICHEM® se voit décerner le prix 2025 IIWCG Achievement Award récompensant l’innovation dans le domaine du soin des plaies
30/04/2025
Reconnu pour ses avancées dans le domaine des soins des plaies à l’échelle mondiale grâce à son caractère innovant et à son efficacité AMSTERDAM, 30 avr. 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, le produit phare de DEBx [...]
DEBRICHEM® Wins 2025 IIWCG Achievement Award for Innovation in Wound Care
30/04/2025
Recognized for Advancing Global Wound Care Through Innovation and Efficacy AMSTERDAM, April 30, 2025 (GLOBE NEWSWIRE) -- DEBRICHEM®, the flagship product of DEBx Medical has been awarded the IIWCG Achievement Award 2025 [...]
Notice of Annual General Meeting 2025
30/04/2025
Oslo, Norway, 30 April 2025 - The annual general meeting of PCI Biotech Holding ASA will be held at the company’s office at Oslo Cancer Cluster Innovation Park on 22 May 2025 at 10:00am (CEST). The notice and proposed [...]
Essential Pharma strengthens Board with the appointment of Jonathan Arnold as Non-Executive Director
30/04/2025
Essential Pharma strengthens Board with the appointment of Jonathan Arnold as Non-Executive Director Egham, UK – 30 April 2025 – Essential Pharma (“Essential” or “the Company”), a global pharmaceutical company [...]
RetinAI and FVS Announce CE-MDR Certification for Co-developed AI-based Diabetic Retinopathy Screening Algorithm, LuxIA®
30/04/2025
BERN, Switzerland and MADRID, April 30, 2025 (GLOBE NEWSWIRE) -- RetinAI US Inc. (RetinAI) and Fundación Ver Salud (FVS) are pleased to jointly announce that LuxIA ® , their co-developed innovative AI algorithm for [...]
Zelluna ASA: Invitation to First Quarter 2025 results webcast presentation
30/04/2025
Oslo, Norway, 30 April 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic ‘off the shelf’ T Cell Receptor based Natural Killer (TCR-NK) cells for the treatment of cancer, invites to a webcast presentation of [...]
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
30/04/2025
Full results from the completed dose escalation part and dose expansion parts of a Phase 1 study evaluating JNJ-1900 (NBTXR3) after induction chemotherapy for patients with locally advanced or borderline resectable [...]
Nanobiotix présente les résultats complets de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) dans le cancer du pancréas et organise une conférence téléphonique et webcast
30/04/2025
L’ensemble des résultats des parties d’escalade et d’expansion de dose de l’étude de Phase 1 évaluant JNJ-1900 (NBTXR3) après chimiothérapie d’induction chez des patients atteints d’un cancer du pancréas localement [...]
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025
30/04/2025
Immuno-Oncology Results from Research Collaboration with Léon Bérard Cancer Center Presented at AACR Annual Meeting 2025 New gene expression signature for cancer patients to predict clinical response to immune [...]
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard - Au congrès annuel de l’AACR 2025
30/04/2025
Présentation des résultats d’une collaboration de recherche en Immuno-Oncologie avec le Centre Léon Bérard Au congrès annuel de l’AACR 2025 Une nouvelle signature d’expression génique pour prédire la réponse clinique [...]
Nicox Provides Full Year 2024 Financial Results
30/04/2025
Press Release Nicox Provides Full Year 2024 Financial Results Nicox SA revenue of €7.9 million for full year 2024 Exceptional income of €13.7 million following the transfer of VYZULTA’s future revenue stream to Soleus [...]
Nicox : Résultats financiers de l’année 2024
30/04/2025
Communiqué de presse Nicox : Résultats financiers de l’année 2024 Chiffre d’affaires de Nicox SA de 7,9 millions d’euros pour l’année 2024 Produits exceptionnels de 13,7 millions d’euros suite à la cession du flux futur [...]
CHMP recommends EU label update for Roche’s Phesgo to allow administration outside of clinical settings
30/04/2025
Positive recommendation based on clinical, real-world and bioequivalence data supporting feasibility and safety of Phesgo’s administration outside of clinical settings, for example at home 1-4 Phesgo label expansion [...]

Pages